ZLZhiquan Liu

Zhiquan Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhiquan Liu has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Siyu Chen

    Department of Ophthalmology, Stanford University School of Medicine, 1651 Page Mill Road, Palo Alto, CA 94304, USA

    9 shared publications
  • Yang Sun

    Department of Ophthalmology, Stanford University School of Medicine

    7 shared publications
  • Liangxue Lai

    Institute of Development and Regeneration, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, China

    5 shared publications
  • Zhanjun Li

    Key Laboratory of Zoonosis Research, Ministry of Education, College of Animal Sciences, Jilin University, Changchun, China

    5 shared publications
  • Mao Chen

    Key Laboratory of Zoonosis Research, Ministry of Education, College of Animal Science, Jilin University, Changchun, 130062 China

    4 shared publications
  • Qing Wang

    Department of Ophthalmology, Stanford University School of Medicine

    4 shared publications

Latest Publications

  • Open Access

    Defective neuronal differentiation in Lowe syndrome is associated with mitochondrial dysfunction and impaired cilia-related Sonic Hedgehog signaling

    by Grzegorz Walkiewicz, Siyu Chen, Chienhui Lo, Jingyu Zhao, Zhiquan Liu, Biao Wang, Qing Wang, Tia J Kowal, Benjamin Lawson, Yang Sun

    Human brain development requires tight coordination of metabolic and signaling pathways. Lowe syndrome (LS) is a recessive X-linked disorder characterized by proximal tubular renal disease, congenital cataracts, glaucoma, and neurodevelopmental delays. While LS results from mutations in the OCRL gene, which encodes an inositol polyphosphate 5-phosphatase, the cellular mechanisms driving neuronal dysfunction remain poorly understood. In this study, using patient-derived iPSC neurons, an Ocrl knockout mouse model, and an independent zebrafish OCRL-deficient model, we identified mitochondrial dysfunction as a conserved phenotype of OCRL loss across species. Collectively, our findings showed that OCRL deficiency leads to reduced mitochondrial activity, decreased mtDNA levels, reduced mitochondrial content (TOM20), and increased oxidative stress. We further showed that OCRL-deficient neural cells exhibited an altered balance of neuronal versus astrocytic differentiation, rather than a defect in neurogenesis. Additionally, we observed impaired Sonic Hedgehog (Shh) signaling and ciliary homeostasis. Thus, our findings support a model in which OCRL deficiency is associated with mitochondrial dysfunction, increased oxidative stress, altered neural lineage balance, and reduced Hedgehog pathway activity, providing a framework for understanding these interconnected phenotypes.

  • Open Access

    CRISPR and Gene Augmentation Rescue Trabecular Meshwork Dysfunction in iPSC Models of Lowe Syndrome

    by Siyu Chen, Zhiquan Liu, Wenmin Wang, Qing Wang, Tia J. Kowal, Fan Zhang, Grzegorz Walkiewicz, Faruk Hossen, Herbert M. Lachman, Jinqiong Zhou, et al.

    Lowe syndrome is a rare, currently incurable multisystem disorder that affects the eyes, kidneys, and central nervous system. It is caused by mutations in the OCRL gene, which encodes an inositol 5‐phosphatase. The disorder remains incurable, and the pathways underlying the ocular symptoms remain poorly understood, largely due to the lack of appropriate models. In this study, trabecular meshwork cell models of Lowe syndrome were generated to test two distinct gene therapy strategies: a mutation‐agnostic OCRL DNA augmentation therapy and a patient‐specific CRISPR‐mediated gene correction strategy. The results showed that AAV2‐OCRL demonstrated the highest transduction efficiency in patient iPSC‐derived trabecular meshwork models (iHTM) among the three AAV‐OCRL vectors evaluated, establishing it as a promising delivery vector. Targeted CRISPR‐based gene therapy restored OCRL enzyme activity and corrected cellular defects in patient iPSC‐derived trabecular meshwork cell models. Furthermore, RNA‐sequencing analysis of these models revealed dysregulation of extracellular matrix organization, cell adhesion, focal adhesion, and cytoskeletal regulatory pathways, suggesting that disruption of interconnected ECM‐adhesion‐cytoskeletal networks may contribute to trabecular meshwork dysfunction in Lowe syndrome‐associated glaucoma. These findings indicate the feasibility of OCRL gene augmentation and CRISPR‐based gene editing in patient‐derived ocular models and position AAV2‐OCRL as a leading therapeutic candidate for Lowe syndrome.

  • Open Access

    TIGRa: An ultra-compact programmable activator enabling multiplexed and efficient gene regulation

    by Zhiquan Liu, Siyu Chen, Wenmin Wang, Fan Zhang, Qing Wang, Grzegorz Walkiewicz, Faruk Hossen, Jinqiong Zhou, Yiting Wang, Yang Sun


  • Open Access

    Defective Neuronal Differentiation in Lowe Syndrome is Associated with Mitochondrial Dysfunction and Impaired Cilia-related Sonic Hedgehog Signaling

    by Grzegorz Walkiewicz, Siyu Chen, Chien-Hui Lo, Jingyu Zhao, Zhiquan Liu, Biao Wang, Benjamin Lawson, Qing Wang, Tia J Kowal, Yang Sun

    Human brain development requires tight coordination of metabolic and signaling pathways. Lowe syndrome (LS) is a recessive X-linked disorder characterized by proximal tubular renal disease, congenital cataracts, glaucoma, and neurodevelopmental delays. While LS results from mutations in the OCRL gene, which encodes an inositol polyphosphate 5-phosphatase, the cellular mechanisms driving neuronal dysfunction remain poorly understood. In this study, using patient-derived iPSC neurons, an OCRL knockout mouse model, and an independent zebrafish OCRL-deficient model, we identified mitochondrial dysfunction as a conserved phenotype of OCRL loss across species. Collectively, our findings showed that OCRL deficiency leads to reduced mitochondrial activity, decreased mtDNA levels, reduced mitochondrial content (TOM20), and increased oxidative stress. We further showed that OCRL-deficient neural cells exhibited an altered balance of neuronal versus astrocytic differentiation, rather than a defect in neurogenesis. Additionally, we observed impaired Sonic Hedgehog (Shh) signaling and ciliary homeostasis. Thus, we propose that mitochondrial dysfunction-induced oxidative stress acts as a central mediator linking OCRL loss to altered cell fate and disrupted Shh signaling, providing a unifying framework for these phenotypes.

  • Open Access

    Gene therapy for ocular hypertension using hfCas13d-mediated mRNA targeting

    by Siyu Chen, Zhiquan Liu, Chien-Hui Lo, Qing Wang, Ke Ning, Qi Zhang, Jingyu Zhao, Yingchun Shen, Yang Sun

    Glaucoma is a major global cause of irreversible vision loss. It is marked by elevated intraocular pressure (IOP) and the loss of retinal ganglion cells (RGC). While there are medical and surgical therapies for glaucoma aiming to reduce aqueous humor production or enhance its drainage, these treatments are often inadequate for effectively managing the disease. In this study, we developed a targeted therapy for glaucoma by knocking down two genes associated with aqueous humor production (aquaporin 1 [AQP1] and carbonic anhydrase type 2 [CA2]) using Cas13 RNA editing systems. We demonstrate that hfCas13d-mediated knockdown of AQP1 and CA2 significantly lowers IOP in wild-type mice and in a corticosteroid-induced glaucoma mouse model. We show that the lowered IOP results from decreasing aqueous production without affecting the outflow facility; this treatment also significantly promotes RGC survival as compared with untreated control groups. Therefore, CRISPR–Cas-based gene editing may be an effective treatment to lower IOP for glaucomatous optic neuropathy.


  • Open Access

    Precise Correction of the Pde6b -L659P Mutation Causing Retinal Degeneration with Minimum Bystander Editing by Advanced Genome Editing Tools

    by Zhiquan Liu, Siyu Chen, Yang Sun

    Recently developed base editing (BE), prime editing (PE), and click editing (CE) technologies enable precise and efficient genome editing with minimal risk of double-strand breaks and associated toxicity. However, their effectiveness in correcting real disease-causing mutations has not been systematically compared. Here, we aim to evaluate the potential of BE, PE, and CE technologies in rescuing the retinal degeneration-causing Pde6b (c.1976T>C, p.L659P) mutation. This site is prone to bystander effects, making it an ideal model for comparing the editing outcomes of these 3 novel technologies, particularly their editing precision. We optimized BE, PE, and CE systems in vitro using Pde6b -L659P cell models and compared their editing via deep sequencing. BE and PE had similar efficiency, but PE was the most precise, minimizing bystander edits. CE had lower efficiency and higher indel rates, needing further optimization. Using the optimal PE system for in vivo electroporation in Pde6b -L659P mice, we achieved 12.4% targeted repair with high precision, partially rescuing retinal degeneration. This study demonstrates proof of concept for the precise correction of the Pde6b -L659P mutation causing retinal degeneration using BE, PE, and CE tools. The findings offer valuable insights into the future optimization of precision gene editing techniques and their potential translational applications.

  • Open Access

    Efficient Rescue of Retinal Degeneration in Pde6a Mice by Engineered Base Editing and Prime Editing

    by Zhiquan Liu, Siyu Chen, Alexander E. Davis, Chien‐Hui Lo, Qing Wang, Tingting Li, Ke Ning, Qi Zhang, Jingyu Zhao, Sui Wang, et al.

    Retinitis pigmentosa (RP) is a complex spectrum of inherited retinal diseases marked by the gradual loss of photoreceptor cells, ultimately leading to blindness. Among these, mutations in PDE6A, responsible for encoding a cGMP‐specific phosphodiesterase, stand out as pivotal in autosomal recessive RP (RP43). Unfortunately, no effective therapy currently exists for this specific form of RP. However, recent advancements in genome editing, such as base editing (BE) and prime editing (PE), offer a promising avenue for precise and efficient gene therapy. Here, it is illustrated that the engineered BE and PE systems, particularly PE, exhibit high efficiency in rescuing a target point mutation with minimal bystander effects in an RP mouse model carrying the Pde6a (c.2009A > G, p.D670G) mutation. The optimized BE and PE systems are first screened in N2a cells and subsequently assessed in electroporated mouse retinas. Notably, the optimal PE system, delivered via dual adeno‐associated virus (AAV), precisely corrects the pathogenic mutation with average 9.4% efficiency, with no detectable bystander editing. This correction restores PDE6A protein expression, preserved photoreceptors, and rescued retinal function in Pde6a mice. Therefore, this study offers a proof‐of‐concept demonstration for the treatment of Pde6a‐related retinal degeneration using BE and PE systems.


  • Open Access

    Inhibition of base editors with anti-deaminases derived from viruses

    by Zhiquan Liu, Siyu Chen, Liangxue Lai, Zhanjun Li

    Cytosine base editors (CBEs), combining cytidine deaminases with the Cas9 nickase (nCas9), enable targeted C-to-T conversions in genomic DNA and are powerful genome-editing tools used in biotechnology and medicine. However, the overexpression of cytidine deaminases in vivo leads to unexpected potential safety risks, such as Cas9-independent off-target effects. This risk makes the development of deaminase off switches for modulating CBE activity an urgent need. Here, we report the repurpose of four virus-derived anti-deaminases (Ades) that efficiently inhibit APOBEC3 deaminase-CBEs. We demonstrate that they antagonize CBEs by inhibiting the APOBEC3 catalytic domain, relocating the deaminases to the extranuclear region or degrading the whole CBE complex. By rationally engineering the deaminase domain, other frequently used base editors, such as CGBE, A&CBE, A&CGBE, rA1-CBE and ABE8e, can be moderately inhibited by Ades, expanding the scope of their applications. As a proof of concept, the Ades in this study dramatically decrease both Cas9-dependent and Cas9-independent off-target effects of CBEs better than traditional anti-CRISPRs (Acrs). Finally, we report the creation of a cell type-specific CBE-ON switch based on a microRNA-responsive Ade vector, showing its practicality. In summary, these natural deaminase-specific Ades are tools that can be used to regulate the genome-engineering functions of BEs.


  • Open Access

    Efficient and precise base editing in rabbits using human APOBEC3A-nCas9 fusions

    by Zhiquan Liu, Siyu Chen, Huanhuan Shan, Quanjun Zhang, Mao Chen, Liangxue Lai, Zhanjun Li


  • Open Access

    Improved base editor for efficient editing in GC contexts in rabbits with an optimized AID‐Cas9 fusion

    by Zhiquan Liu, Huanhuan Shan, Siyu Chen, Mao Chen, Quanjun Zhang, Liangxue Lai, Zhanjun Li

    Cytidine base editors, which are composed of a cytidine deaminase fused to clustered regularly interspaced short palindromic repeat (CRISPR)–associated protein 9 (Cas9) nickase, enable the efficient conversion of the C·G base pair to T·A in various organisms. However, the currently used rat apolipoprotein B mRNA‐editing enzyme, catalytic polypeptide 1(rA1)–based BE3 is often inefficient in target Cs that are immediately downstream of a G (GC context). Here, we observed that, with an 11‐nt editing window, an optimized activation‐induced cytidine deaminase (AID)‐Cas9 fusion can efficiently convert C to T in a variety of sequence contexts in rabbits. Strikingly, the enhanced AID‐Cas9 fusion (eAID‐BE4max) has significant effectiveness of inducing Tyr p.R299H mutation in GC contexts (from 16.67 to 83.33%) in comparison with BE3 in founder rabbits. Furthermore, the engineered AID‐Cas9 variants were produced with reduced bystander activity [eAID (N51G)‐BE4max] and increased genome‐targeting scope (eAID‐NG‐BE4max). Overall, this work provides a series of improved tools that were generated using optimized AID‐Cas9 fusions and associated engineered variants that can be used for efficient and versatile C‐to‐T base editing, especially in GC contexts.—Liu, Z., Shan, H., Chen, S., Chen, M., Zhang, Q., Lai, L., Li, Z. Improved base editor for efficient editing in GC contexts in rabbits with an optimized AID‐Cas9 fusion. FASEB J. 33, 9210–9219 (2019). www.fasebj.org